Substance
ID:349151
Names and Identifiers
IUPAC Traditional name
4-[5-(4-butylcyclohexyl)-1,2,4-oxadiazol-3-yl]pyridine
IUPAC name
4-[5-(4-butylcyclohexyl)-1,2,4-oxadiazol-3-yl]pyridine
Synonyms
4-[5-(4-butylcyclohexyl)-1,2,4-oxadiazol-3-yl]-pyridinePSN-375963
Properties
Safety Information
Product Information
Purity
≥98% (HPLC)
Empirical Formula (Hill Notation)
C17H23N3O
Physical Property
Apperance
white to off-white powder
Solubility
DMSO: >10 mg/mL
Molecule Details
Biochem/physiol Actions
PSN-375963 is a GPR119 partial agonist. GPR119 is an orphan GPCR, expressed predominantly in pancreas and GI tract, that has been characterized. Its endogenous ligands are oleoylethanolamide (OEA) and oleoyl-lysophosphatidylcholine, lipid signaling molecules that regulate food intake and body weight. OEA decreases food intake, so GPR119 agonists are potential therapies for obesity. Initial studies showed that PSN-375963 has similar potency and partial efficacy compared to OEA. Further studies revealed that although OEA and PSN-375963 are GPR119 agonists, they have divergent effects on insulin secretion, calcium signaling, and cAMP production.
PSN-375963 is a GPR119 partial agonist. GPR119 is an orphan GPCR, expressed predominantly in pancreas and GI tract, that has been characterized. Its endogenous ligands are oleoylethanolamide (OEA) and oleoyl-lysophosphatidylcholine, lipid signaling molecules that regulate food intake and body weight. OEA decreases food intake, so GPR119 agonists are potential therapies for obesity. Initial studies showed that PSN-375963 has similar potency and partial efficacy compared to OEA. Further studies revealed that although OEA and PSN-375963 are GPR119 agonists, they have divergent effects on insulin secretion, calcium signaling, and cAMP production.
Molecular Spectra
No Data Available
Click here to submit data
References
No Data Available
Click here to submit data